Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

导出 LinkOut

翻译打印收藏纠错

作者： H H,Milioli ^[1] ; S,Alexandrou ^[2] ; E,Lim ^[1] ; C E,Caldon ^[1]

作者单位： Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia. ^[1] St Vincent's Clinical School, UNSW Sydney, Sydney, New South Wales, Australia. ^[2]

关键词 CDK4/6 inhibitors breast cancer cyclin E1 cyclin E2 endocrine therapy resistance

主题词乳腺肿瘤(Breast Neoplasms);细胞周期蛋白类(Cyclins);雌激素类(Estrogens);女(雌)性(Female);人类(Humans)

DOI 10.1530/ERC-19-0501

PMID 32061162

发布时间 2021-08-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Endocrine-related cancer

2020年27卷5期

R93-R112页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Endocrine-related cancer

相似文献

Endocrine-related cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Endocrine-related cancer

相似文献

Endocrine-related cancer

相关期刊

检索历史清除